Advertisement
Australia markets close in 1 hour 13 minutes

  • ALL ORDS

    8,030.60
    +78.30 (+0.98%)
     

  • ASX 200

    7,757.80
    +75.40 (+0.98%)
     

  • AUD/USD

    0.6609
    -0.0017 (-0.25%)
     

  • OIL

    78.62
    +0.14 (+0.18%)
     

  • GOLD

    2,330.70
    -0.50 (-0.02%)
     

  • Bitcoin AUD

    95,985.17
    -1,154.14 (-1.19%)
     

  • CMC Crypto 200

    1,364.03
    +51.40 (+3.92%)
     

  • AUD/EUR

    0.6137
    -0.0009 (-0.15%)
     

  • AUD/NZD

    1.0995
    -0.0025 (-0.23%)
     

  • NZX 50

    11,794.70
    -26.08 (-0.22%)
     

  • NASDAQ

    18,093.57
    +202.77 (+1.13%)
     

  • FTSE

    8,213.49
    +41.34 (+0.51%)
     

  • Dow Jones

    38,852.27
    +176.59 (+0.46%)
     

  • DAX

    18,175.21
    +173.61 (+0.96%)
     

  • Hang Seng

    18,420.38
    -157.92 (-0.85%)
     

  • NIKKEI 225

    38,803.30
    +567.23 (+1.48%)
     

What's the Outlook for Illumina?

Keith Speights and Brian Orelli, PhD, The Motley Fool
·3-min read

Genomic sequencing leader Illumina (NASDAQ: ILMN) recently provided guidance for 2022 and revealed some of its plans for the year. In this Motley Fool Live video, recorded on Jan. 12, Fool contributors Keith Speights and Brian Orelli discuss the outlook for Illumina going forward. Keith Speights: Hey, there's a company that you and I haven't talked about very much, at least, I'm going to say at least over the last seven or eight months and maybe longer than that.

Continue reading